Funded in part by Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Teva Pharmaceutical Industries, CeNeRx, Pharmavite, ACADIA Pharmaceuticals, Avanir Pharmaceuticals, Cerecor, FORUM Pharmaceuticals, Belvoir Media Group, Janssen Research and Development
Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial
Cassano P, Petrie SR, Mischoulon D, Cusin C, Katnani H, Yeung A, De Taboada L, Archibald A, Bui E, Baer L, Chang T, Chen J, Pedrelli P, Fisher L, Farabaugh A, Hamblin MR, Alpert JE, Fava M, Iosifescu DV
Photomedicine and laser surgery · 79 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Nonprofit
- Brain and Behavior Research Foundation
- Company
- Abbott Laboratories
- Company
- Bristol-Myers Squibb
- Company
- Eli Lilly and Company
- Company
- Pfizer
- Company
- AstraZeneca
- Company
- GlaxoSmithKline
- Company
- Sanofi
- University or hospital
- Massachusetts General Hospital
- Company
- Teva Pharmaceutical Industries
- Company
- CeNeRx
- Company
- Pharmavite
- Nonprofit
- National Alliance for Research on Schizophrenia and Depression
- Company
- ACADIA Pharmaceuticals
- Company
- Avanir Pharmaceuticals
- Company
- Cerecor
- Nonprofit
- American Society of Clinical Psychopharmacology
- Company
- FORUM Pharmaceuticals
- Company
- Belvoir Media Group
- Government
- National Institutes of Health
- Government
- National Institute of Allergy and Infectious Diseases
- Government
- National Institute of Neurological Disorders and Stroke
- Company
- Janssen Research and Development
- Government
- NIAID NIH HHS
- Grants
- Brain and Behavior Research Foundation (19159); National Institute of Allergy and Infectious Diseases (R01 AI050875); National Institute of Allergy and Infectious Diseases (R21 AI121700)
Based on 24 listed funder(s).
Publication
- Published
- 2018-10-22 · Photomed Laser Surg · vol. 36 · issue 12 · pp. 634–646
- Publisher
- Mary Ann Liebert, Inc.
- Cited
- 157 citations · more than 97% of similar papers · 5.8× the field average
- Impact
- Top 10% most cited in its field
- References
- 62 works
- Access
- Open access (repository copy)
- Research areas
- Laser Applications in Dentistry and Medicine · Medical and Biological Ozone Research · Migraine and Headache Studies
- Keywords
- Antidepressant, Major depressive disorder, Medicine, Adverse effect, Dorsolateral prefrontal cortex, Depression (economics), Neuroplasticity, Internal medicine, Prefrontal cortex, Anesthesia, Psychiatry, Mood, Cognition
- MeSH
- humans, pilot projects, double-blind method, randomized controlled trials as topic, low-level light therapy, major depressive disorder
19 authors
From US, GB
- Paolo Cassano · correspondingMassachusetts General Hospital; National Center for Post Traumatic Stress Disorder
- Samuel R. PetrieMassachusetts General Hospital
- David MischoulonMassachusetts General Hospital
- Cristina CusinMassachusetts General Hospital
- Husam A. KatnaniMassachusetts General Hospital
- Albert YeungMassachusetts General Hospital
Abstract
Objective: Our objective was to test the antidepressant effect of transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light in subjects suffering from major depressive disorder (MDD). Background: t-PBM with NIR light is a new treatment for MDD. NIR light is absorbed by mitochondria; it boosts cerebral metabolism, promotes neuroplasticity, and modulates endogenous opioids, while decreasing inflammation and oxidative stress. Materials and methods: We conducted a double-blind, sham-controlled study on the safety and efficacy [change in Hamilton Depression Rating Scale (HAM-D17) total score at end-point] of adjunct t-PBM NIR [823 nm; continuous wave (CW); 28.7 × 2 cm2; 36.2 mW/cm2; up to 65.2 J/cm2; 20-30 min/session], delivered to dorsolateral prefrontal cortex, bilaterally and simultaneously, twice a week, for 8 weeks, in subjects with MDD. Baseline observation carried forward (BOCF), last observation carried forward (LOCF), and completers analyses were performed. Results: The effect size for the antidepressant effect of t-PBM, based on change in HAM-D17 total score at end-point, was 0.90, 0.75, and 1.5 (Cohen's d), respectively for BOCF (n = 21), LOCF (n = 19), and completers (n = 13). Further, t-PBM was fairly well tolerated, with no serious adverse events. Conclusions: t-PBM with NIR light demonstrated antidepressant properties with a medium to large effect size in patients with MDD. Replication is warranted, especially in consideration of the small sample size.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.